Carregant...
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AboutScience Srl
2018-10-01
|
| Col·lecció: | AboutOpen |
| Matèries: | |
| Accés en línia: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|